Broad Institute

The quarterly Venture Monitor report from Pitchbook and the National Venture Capital Association (NVCA) reported biopharma start-ups raised $5.9bn in the first quarter of 2024 – more than the sector r

Venture capital investment in biopharmaceutical companies ticked higher in the first quarter of 2024. In the second quarter, money is flowing into VC investors and funds focused specifically on the li

Broad Institute co-founder Stuart Schreiber is teaming up with an all-star list of scientists and financial backers to found Arena BioWorks, which Schreiber said is intended to let scientists focus o

The approval of the first genetic medicines for sickle cell disease (SCD) on the eve of the American Society of Hematology (ASH) annual meeting set off a celebratory feel for the conference, held 9-12